Modified biological peptides with increased potency

Description

FIELD OF THE INVENTION

[0001] The present invention is concerned with modified peptides providing increased biological potency, prolonged activity and/or increased half-life thereof. The modification is made via coupling through an amide bond with at least one conformationally rigid substituent either at the N-terminal of the peptide, the C-terminal of the peptide, or a free amino or carboxyl group along the peptide chain, or at a plurality of these sites.

BACKGROUND OF THE INVENTION

[0002] Most peptides are rapidly degraded in a serum medium and as a result, their metabolites may sometimes end up with little or no residual biological activity. To increase the activity of a peptide, various techniques have been proposed. One of them is to anchor a hydrophobic chain at the N- or C-terminal of the peptidic sequence or at other residues along the peptidic chain. This technique nevertheless has limitations. For example, if the peptide comprises a long peptidic chain, the fact that a small hydrophobic group is anchored to the N- or C-terminal does not necessarily result in an increased activity of the peptide so-modified.

[0003] For example, it is known that substituting OH for a more hydrophobic group like —NEt2 at the C-terminal of a peptide sequence can result in a significantly increased specific activity. However, these results are contradicted by several publications, such as Muranichi et al. in Pharm. Res., 1991, 8, 649-652, which stresses the inefficiency of a lauroyl group as a hydrophobic group at the N-terminal to increase activity. Accordingly, there does not seem to be any general rule or conclusion concerning biological potency, duration of activity and/or half life, that can be derived as a result of the addition of substituents on a peptide chain, whether at the N- or C-terminal, or on certain residues along the peptidic chain.

[0004] U.S. Pat. No. 6,020,311 discloses a hydrophobic growth hormone-releasing factor (GRF) analog wherein a rigidified hydrophobic moiety is coupled to the GRF peptide via an amide bond at the N-terminal of the peptide. Such analog is said to have an improved anabolic potency with reduced dosage, and a prolonged activity. According to the teaching of this patent, however, the rigidified hydrophobic moiety always comprises a carbonyl group at one extremity, which means that an amide coupling thereof to the GRF can only take place at an amino site to form the required amide bond. The patent does not mention, suggest or imply that similar results could be obtained if the amide coupling was made at the C-terminal by replacing the carbonyl group on the rigidified hydrophobic moiety with an amino group. The patent does not further mention, suggest or imply that the amide coupling could take place elsewhere on the peptide chain.

[0005] Biochemistry 2001, 40, pages 2860 to 2869 describes an hydrophobic glucagon-like peptide-1 (GLP-1) analog wherein hexanoic acid, a rigidified hydrophobic moiety is coupled to the GLP-1 peptide at the N-terminal of the peptide. The results show that this analog exhibits a decreased affinity for the GLP-1 receptor, but an in vivo bioactivity similar to or slightly better than that of the wild type GLP-1, hypothetically because of increased resistance to serum degradation. According to this study, the linkage of acyl chains to His1, amino-acid substitutions of Ala2, and the addition of amino-acid sequences at the N-terminal of the molecule would be better strategies to increase the in vivo biological activity than anchoring rigidified hydrophobic chains. However, most of these strategies involve a modification of the amino-acid composition of the natural molecule, which might have negative safety consequences for clinical applications, including the risks for immunogenicity and side effects.

[0006] There is therefore a great need to develop peptides modified in a manner such that their activity will be increased, thereby improving their potency, i.e., greater resistance to serum degradation and/or from hyperagonistic properties, and/or is increasing their half-life without changing the amino-acid sequence that would be clinically safe and acceptable.

SUMMARY OF THE INVENTION

[0007] In accordance with the present invention, there is now provided a peptide of formula Xn—R1 wherein:

[0008] R1 is a peptide sequence which cannot be the GRF sequence when X represents a trans-3-hexanoyl group attached at N-terminal position of the peptide sequence;

[0009] each X can be identical or independent from the others and is selected from the following list constituted by conformationally rigid moieties bearing:

[0010] a) a carboxy or an amino group for coupling with the peptide sequence via an amide bond at the N-terminal of the peptide sequence, the C-terminal of the peptide sequence, at an available carboxy or amino site on the peptide sequence chain, and combinations thereof; and

[0011] b) a carboxy group for coupling with the peptide sequence via an ester bond at an available hydroxy site on the peptide sequence chain, and combinations thereof;

[0012] wherein,

[0013] n is any digit between 1 to 5;

[0014] X being defined as:

[0015] i) a straight, substituted C1-C10 alkyl;

[0016] ii) a branched, substituted C1-C10 alkyl;

[0017] iii) a straight or branched, unsubstituted or substituted C1-C10 alkene;

[0018] iv) a straight or branched, unsubstituted or substituted C1-C10 alkyne;

[0019] v) an unsubstituted or substituted, saturated or unsaturated C3-C10 cycloalkyl or heterocycloalkyl wherein the heteroatom is O, S or N;

[0020] vi) an unsubstituted or substituted C5-C14 aryl or heteroaryl wherein the heteroatom is O, S or N;

[0021] wherein the substituent in the definitions i) to vi) comprises one or more

[0022] a) straight or branched C1-C6 alkyl;

[0023] b) straight or branched C1-C6 alkene;

[0024] c) straight or branched C1-C6 alkyne;

[0025] d) C3-C10 cycloalkyl or heterocycloalkyl wherein at least 2 carbon atoms are optionally connected to the C1-C10 alkyl, C1-C10 alkene, C1-C10 alkyne, C3-C10 cycloalkyl or heterocycloalkyl, and C5-C14 aryl or heteroaryl; or

[0026] e) C5-C14 aryl or heteroaryl wherein at least 2 carbon atoms of the aryl or heteroaryl are optionally connected to the C1-C10 alkyl, C1-C10 alkene, C1-C10 alkyne, C3-C10 cycloalkyl or heterocycloalkyl, and C5-C14 aryl or heteroaryl;

[0027] and any isomers thereof, including cis and trans configurations, epimers, enantiomers, diastereoisomers, and racemic mixtures.

[0028] The term “aryl” includes phenyl, naphthyl and the like; the term “heterocycloalkyl” includes tetrahydrofuranyl, tetrahydrothiophanyl, tetrahydrothiopyranyl, tetrahydropyranyl and partially dehydrogenated derivatives thereof, azetidinyl, piperidinyl, pyrrolidinyl, and the like; the term “heteroaryl” comprises pyridinyl, indolyl, furanyl, imidazolyl, thiophanyl, pyrrolyl, quinolinyl, isoquinolinyl, pyrimidinyl, oxazolyl, thiazolyl, isothiazolyl, isooxazolyl, pyrazolyl, and the like.

[0029] The expression “conformationally rigid moiety” means an entity having limited conformational, i.e., rotational, mobility about its single bonds. Such mobility is limited, for example, by the presence of a double bond, a triple bond, or a saturated or unsaturated ring, which have little or no conformational mobility. As a result, the number of conformers or rotational isomers is reduced when compared, for example, with the corresponding straight, unsubstituted and saturated aliphatic chain. The conformationally rigid moiety may be hydrophobic, although this is not a prerequisite.

[0030] According to a preferred embodiment of the present invention the peptide sequence is selected from the group consisting of Growth hormone releasing factor (GRF), Somatostatin, Glucagon-like peptide 1 (7-37), amide human (GLP-1), hGLP-1 (7-36) NH2 Parathyroid hormone fragments such as (PTH 1-34), Adrenocorticotropic hormone (ACTH), Osteocalcin, Calcitonin, Corticotropin releasing factor, Dynorphin A, β-Endorphin, Big Gastrin-1, GLP-2, Luteinizing hormone-releasing hormone, Melanocyte Stimulating Hormone (MSH), Atrial Natriuretic Peptide, Neuromedin B, Human Neuropeptide Y, Human Orexin A, Human Peptide YY, Human Secretin, Vasoactive Intestinal peptide (VIP), Antibiotic peptides (Magainin 1, Magainin 2, Cecropin A, and Cecropin B), Substance P (SP), Beta Casomorphin-5, Endomorphin-2, Procolipase, Enterostatin, gastric inhibitory peptide, Chromogranin A, Vasostatin I & II, Procalcitonin, ProNCT, ProCGRP, IL8 (monocyte-derived), GCP-2, PF4, IP-10, MIG, SDF-1α, GRO-α, I-TAC, RANTES, LD78, MIP-1α, MCP-1, MCP-2, MCP-3, MCP-4, Eotaxin, MDC, and functional derivatives or fragments thereof.

DETAILED DESCRIPTION OF THE INVENTION

[0031] The amino acids are identified in the present application by the conventional three-letter abbreviations as indicated below, which are as generally accepted in the peptide art as recommended by the IUPAC-IUB commission in biochemical nomenclature:

1AlanineAlaLeucineLeuArginineArgLysineLysAsparagineAsnMethionineMetAspartic acidAspPhenylalaninePheCyesteineCysProlineProGlutamic acidGluSerineSerGlutamineGlnThreonineThrGlycineGlyTryptophanTrpHistidineHisTyrosineTyrIsoleucineIleValueVal

[0032] All the peptide sequences set out herein are written according to the generally accepted convention whereby the N-terminal amino acid is on the left and the C-terminal amino acid is on the right.

[0033] The present invention relates to the use of at least one conformationally rigid moiety, to produce a new family of peptides with enhanced pharmacological properties.

[0034] The modified peptides of the present invention are prepared according to the following general method, well known in the art of solid phase synthesis.

[0035] Conformationally rigid moieties comprising a carboxy group are used for anchoring to amino groups such as those found on the lysine side chain as well as the N-terminus of peptides. Those comprising an amino group are used for anchoring to carboxyl groups such as those found on the aspartic or glutamic acid side chains or the C-terminus of peptides. For such cases, the anchoring reaction is preferably performed on a solid phase support (Merrifield R. B. 1963, J. Am. Chem. Soc., 1963, 85, 2149 and J. Am. Chem. Soc., 1964, 86, 304) using Benzotriazole-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate described by Castro in the article (B. Castro et al., 1975, Tetrahedron letters, Vol. 14:1219).

[0036] With respect to the anchoring dynamic, the preferred working temperatures are between 20° C. and 60° C. The anchoring reaction time in the case of the more hydrophobic moieties, varies inversely with temperature, and varies between 0.1 and 24 hours.

[0037] Synthesis steps were carried out by solid-phase methodology on a manual peptide synthesizer using the Fmoc strategy. Fmoc amino acids were supplied by Chem Impex International Inc. Chicago and other commercial sources. Sequential Fmoc chemistry using BOP as coupling reagent was applied to the PL-Wang resin (Polymer Laboratories, catalog number: 1463-4799) for the production of the C-terminal carboxylic acid.

[0038] Fmoc deprotections were accomplished with piperidine 20% solution in DMF in three consecutive steps. Always under nitrogen scrubbing, a first solution of piperidine 20% was used for 1 min. to remove the major part of the Fmoc protecting groups. Then, the solution was drained, and another fresh piperidine 20% solution was introduced this time for 3 min., drained again and finally another solution of piperidine 20% for 10 min. The peptide-resin was then washed 4 times successively with 50 mL of DMF under nitrogen scrubbing. After completion of the synthesis, the resin was well washed with DMF and DCM prior to drying.

[0039] Final cleavage of side chain protecting groups and peptide-resin bonds were performed using the following mixture: TFA, ethanedithiol, triisopropylsilane, thioanisole, phenol, water (92:1.66:1.66:1.66:1:2). A final concentration of 20 mL of cleavage cocktail per gram of dried peptide-resin was used to cleave the peptide from the resin. The cleavage reaction was performed at room temperature for 2 hours. The free peptide, now in solution in the TFA cocktail, was then filtered on a coarse fritted disk funnel. The resin was then washed 3 times with pure TFA. The peptide/TFA mixture was evaporated under vacuum on a Rotary evaporator, precipitated and washed with ether prior to its dissolution in water and freeze drying to eliminate the remaining traces of solvent and scavengers.

[0040] Coupling of the First Fmoc-Amino Acid to the Wang Resin

[0041] We used 4-alkoxybenzyl alcohol polystyrene (Wang resin) and 2 eq of the desired Fmoc-amino acid in DMF and let both products mix together under nitrogen scrubbing for 15 min at room temperature. Then 3.3 eq of pyridine and 2 eq of 2,6-dichlorobenzoylchloride were added successively and the reaction was carried out under nitrogen scrubbing for 15-20 hours. (Seiber P., 1987, Tetrahedron Letters, Vol. 28, No. 49, pp 6147-6150). After this reaction, the reaction vessel was drained and the resin washed 4 times successively with DMF under nitrogen scrubbing. Any remaining hydroxyl groups of the resin were benzoylated with 3 eq of benzoylchloride and pyridine in DCE (dichloroethane) for 2 hours.

[0042] Coupling of Each Remaining Amino Acid on the Growing Peptide

[0043] For each of the following Fmoc-amino acid we dissolved 3 eq of the Fmoc-amino acid with 3 eq of BOP (Benzotriazole-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate) (B. Castro et al., 1975, Tetrahedron letters, Vol. 14:1219) in DMF, added the resulting solution to the resin in the reaction vessel, started the nitrogen scrubbing and added 6 eq of DIPEA (diisopropylethylamine) to start the coupling reaction. The coupling mixture was scrubbed under nitrogen for 60 min. in the reaction vessel; then drained from the vessel, the resin was washed 3 times successively with DMF and a qualitative ninhydrin test was performed to verify completion of the reaction.

[0044] The coupling of the Fmoc-L-Lys(Aloc)-OH (PerSeptive Biosystems, catalog number: GEN911209), Fmoc-L-Glu(OAl)-OH (PerSeptive Biosystems, catalog number: GEN911207) and Fmoc-L-Asp(OAl)-OH (PerSeptive Biosystems, catalog number: GEN911205) were carried out in the same way as for the Fmoc-amino acids as described above.

[0045] Deprotection of Allylic Groups

[0046] The peptide-resin (X mmol) was then introduced in DCM under nitrogen scrubbing and after 10 min. the PdCl2(PPh3)2 (X mmol×0.05/0.05 eq) (palladium(II) bis-triphenylphosphine) was added to the mixture (Bürger H., Kilion W., J. Organometallics, 1969, 18:299). Then the (CH3CH2CH2)3SnH (X mmol×6/6 eq) (tributyltinhydride) was diluted in DCM and added dropwise to the peptide-resin suspension with an addition funnel over a period of 30 minutes. The reaction was continued for another 10 minutes then the vessel was drained from the cleavage mixture and right after the peptide-resin was washed 4 times with DCM and 4 times with DMF (Dangles O., Guibe F., Balavoine G., Lavielle S., Marquet A., 1987, J. Org. Chem., 52:4984).

[0047] Coupling of the Conformationally Rigid Acids and Alkylamines

[0048] The coupling of the conformationally rigid acids and amines to the side chains of the peptide-resin was conducted under the same conditions as those of the Fmoc-amino acids except that for these side chain modifications we used 10 equivalents of the rigid moieties and coupling reagent instead of 3.

[0049] The invention is not limited to any particular peptide sequence. Preferred peptide sequences R1 comprise those with therapeutic properties, as well as functional derivatives or fragments thereof. The therapeutic properties of such peptides which may be used in accordance with the present invention include, without limitation, treatment of bone diseases including osteoporosis, postmenopausal osteoporosis and bone deposits, cancer treatment, regulating blood glucose, type II diabetes, treatment to enhance mucosal regeneration in patients with intestinal diseases, treatment for diseases related to inflammatory responses, obesity treatment, treatment for autism and pervasive development disorders, hyperproliferative skin conditions, aging, altering the proliferation of peripheral blood mononuclear cells, regulation of myometrial contractility and of prostaglandin release, stimulation of ACTH release, inhibition of interleukin-8 production, stimulation of acid release, enhancement of mucosal regeneration in patients with intestinal diseases, treatment for hormone-dependent diseases and conditions including for hormone-dependent cancers, modulation of melanocyte information process, involved in pressure and volume homeostasis, regulation of exocrine and endocrine secretions, smooth muscle contraction, feeding, blood pressure, blood glucose, body temperature and cell growth, regulation of food intake and energy balance, inhibition of cancer cell growth, stimulation of pancreatic secretion, or stimulate cell growth.

[0050] Growth Hormone Releasing Factor (GRW):

[0051] Xaa1-Xaa2-Asp-Ala-Ile-Phe-Thr-Xaa8-Ser-Tyr-Arg-Lys-Xaa13-Leu-Xaa15-Gln-Leu- Xaa18-Ala-Arg-Lys-Leu-Leu-Xaa24-Xaa25-Ile-Xaa27-Xaa28-Arg-Gln-Gln-Gly-Glu-Ser- Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

[0052] wherein,

[0053] Xaa1 is Tyr or His;

[0054] Xaa2 is Val or Ala;

[0055] Xaa8 is Asn or Ser;

[0056] Xaa13 is Val or Ile;

[0057] Xaa15 is Ala or Gly;

[0058] Xaa18 is Ser or Tyr;

[0059] Xaa24 is Gln or His;

[0060] Xaa25 is Asp or Glu;

[0061] Xaa27 is Met, Ile or Ile; and

[0062] Xaa28 is Ser or Asn.

[0063] Somatostatin:

[0064] wherein,

[0065] Xaa12 is Tyr or Ser.

[0066] Glucagon-Like Peptide 1 (7-37), (Amide Human (hGLP-1)):

[0067] His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH(NH2)

[0068] Parathyroid Hormone Fragments (PTH 1-34):

[0069] Xaa1-Val-Ser-Glu-Xaa5-Gln-Xaa7-Met-His-Asn-Leu-Gly-Xaa13-His-Xaa15-Xaa16- Xaa17-Xaa18-Glu-Arg-Xaa21-Xaa22-Trp-Leu-Xaa25-Xaa26-Lys-Leu-Gln-Asp-Val-His- Xaa33-Xaa34-NH2

[0070] wherein,

[0071] Xaa1 is Ser or Ala;

[0072] Xaa5 is Ile or Met;

[0073] Xaa7 is Leu or Phe;

[0074] Xaa13 is Lys or Glu;

[0075] Xaa15 is Leu or Arg;

[0076] Xaa16 is Asn or Ala or Ser or His;

[0077] Xaa17 is Ser of Thr;

[0078] Xaa18 is Met or Val or Leu;

[0079] Xaa21 is Val or met or Gln;

[0080] Xaa22 is Glu or Gln or Asp;

[0081] Xaa25 is Arg or Gln;

[0082] Xaa26 is Lys or Met;

[0083] Xaa33 is Asn or Ser; and

[0084] Xaa34 is Phe or Ala.

[0085] Adrenocorticotropic Hormone (ACTH):

[0086] Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Xaa13-Gly-Xaa15-Lys-Arg-Arg- Pro-Xaa20-Lys-Val-Tyr-Pro-Asn-Xaa26-Xaa27-Xaa28-Xaa29-Glu-Xaa31-Xaa32-Glu- Xaa34-Xaa35-Xaa36-Xaa37-Glu-Xaa39-NH2

[0087] wherein,

[0088] Xaa13 is Val or Met;

[0089] Xaa15 is Lys or Arg;

[0090] Xaa20 is Val or Ile;

[0091] Xaa26 is Gly or Ser;

[0092] Xaa27 is Ala or Phe or Val;

[0093] Xaa28 is Glu or Gln;

[0094] Xaa29 is Asp or Asn or Glu;

[0095] Xaa31 is Ser or Thr;

[0096] Xaa32 is Ala or Val or Ser;

[0097] Xaa34 is Ala or Asn or Gly;

[0098] Xaa35 is Phe or Met;

[0099] Xaa36 is Pro or Gly;

[0100] Xaa37 is Leu or Val or Pro; and

[0101] Xaa39 is Phe or Val or Leu.

[0102] Osteocalcin:

[0103] Tyr-Leu-Xaa52-Xaa53-Xaa54-Leu-Gly-Ala-Pro-Xaa59-Pro-Tyr-Pro-Asp-Pro-Leu-Glu- Pro-Xaa68-Arg-Glu-Val-Cys-Glu-Leu-Asn-Pro-Xaa77-Cys-Asp-Glu-Leu-Ala-Asp- His-Ile-Gly-Phe-Gln-Xaa89-Ala-Tyr-Xaa92-Arg-Xaa94-Tyr-Gly-Xaa97-Val-NH2

[0104] wherein,

[0105] Xaa52 is Tyr or Asp or Asn;

[0106] Xaa53 is Gln or His or Asn;

[0107] Xaa54 is Trp or Gly;

[0108] Xaa59 is Val or Ala;

[0109] Xaa68 is Arg or Lys or His;

[0110] Xaa77 is Asp or Asn;

[0111] Xaa89 is Glu or Asp;

[0112] Xaa92 is Arg or Lys;

[0113] Xaa94 is Phe or Ile; and

[0114] Xaa97 is Pro or Thr.

[0115] Calcitonin:

[0116] Cys-Xaa86-Xaa87-Leu-Ser-Thr-Cys-Xaa92-Leu-Gly-Xaa95-Xaa96-Xaa97-Xaa98-Xaa99- Xaa100-Xaa101-Xaa102-Xaa103-Xaa104-Thr-Xaa106-Xaa107-Xaa108-Xaa109- Xaa110-Xaa111-Gly-Xaa113-Xaa114-Xaa115-Pro-NH2

[0117] wherein,

[0118] Xaa86 is Gly or Ser or Ala;

[0119] Xaa87 is Asn or Ser;

[0120] Xaa92 is Met or Val;

[0121] Xaa95 is Thr or Lys;

[0122] Xaa96 is Tyr or Leu;

[0123] Xaa97 is Thr or Ser;

[0124] Xaa98 is Gln or Lys;

[0125] Xaa99 is Asp or Glu;

[0126] Xaa100 is Phe or Leu;

[0127] Xaa101 is Asn or His;

[0128] Xaa102 is Lys or Asn;

[0129] Xaa103 is Phe or Leu;

[0130] Xaa104 is His or Gln;

[0131] Xaa106 is Phe or Tyr;

[0132] Xaa107 is Pro or Ser;

[0133] Xaa108 is Gln or Gly or Arg;

[0134] Xaa109 is Thr or Ile;

[0135] Xaa110 is Ala or Gly or Ser or Asp or Asn;

[0136] Xaa111 is Ile or Phe or Val or Thr;

[0137] Xaa113 is Val or Ala or Ser;

[0138] Xaa114 is Gly or Glu; and

[0139] Xaa115 is Ala or Thr.

[0140] Corticotropin Releasing Factor:

[0141] Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu- Glu-Met-Xaa101-Xaa102-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2

[0142] wherein,

[0143] Xaa101 is Ala or Pro; and

[0144] Xaa102 is Arg or Gly.

[0145] Dynorphin A:

[0146] H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH

[0147] β-Endorphin:

[0148] H-Tyr-Gly-Gly-Phe-Met-Thr-Xaa243-Glu-Xaa245-Ser-Gln-Thr-Pro-Leu-Xaa251-Thr- Leu-Phe-Lys-Asn-Ala-Ile-Xaa259-Lys-Asn-Xaa262-Xaa263-Lys-Lys-Gly-Xaa267-OH

[0149] wherein,

[0150] Xaa243 is Ser or Pro;

[0151] Xaa245 is Lys or Arg;

[0152] Xaa251 is Val or Met;

[0153] Xaa259 is Ile or Val;

[0154] Xaa262 is Ala or Thr or Ser or Val;

[0155] Xaa263 is Tyr or His; and

[0156] Xaa267 is Glu or Leu or Gln or His.

[0157] Big Gastrin-1:

[0158] pXaa59-Leu-Gly-Xaa62-Gln-Xaa64-Xaa65-Xaa66-Xaa67-Xaa68-Xaa69-Ala-Asp-Xaa72- Xaa73-Lys-Lys-Xaa76-Xaa77-Pro-Xaa79-Xaa80-Glu-Xaa82-Glu-Glu-Xaa85-Ala-Tyr-Gly- Trp-Met-Asp-Phe-NH2

[0159] wherein,

[0160] Xaa59 is Glu or Gln;

[0161] Xaa62 is Pro or Leu;

[0162] Xaa64 is Gly or Asp;

[0163] Xaa65 is Pro or Ser;

[0164] Xaa66 is Pro or Gln;

[0165] Xaa67 is His or Gln;

[0166] Xaa68 is Leu or Met or Phe or Gln;

[0167] Xaa69 is Val or Ile;

[0168] Xaa72 is Pro or Leu;

[0169] Xaa73 is Ser or Ala;

[0170] Xaa76 is Gln or Glu;

[0171] Xaa77 is Gly or Arg;

[0172] Xaa79 is Trp or Pro or Arg;

[0173] Xaa80 is Leu or Val or Met;

[0174] Xaa82 is Glu or Lys; and

[0175] Xaa85 is Glu or Ala.

[0176] GLP-2:

[0177] His-Ala-Asp-Gly-Ser-Phe-Xaa152-Xaa153-Xaa154-Xaa155-Xaa156-Xaa157-Xaa158-Leu-Asp- Xaa161-Xaa162-Ala-Xaa164-Xaa165-Xaa166-Phe-Xaa168-Xaa169-Trp-Xaa171-Xaa172- Xaa173-Thr-Xaa175-Xaa176-Xaa177-Xaa178;

[0178] wherein,

[0179] Xaa152 is Ser or Thr;

[0180] Xaa153 is Asp or Ser;

[0181] Xaa154 is Glu or Asp;

[0182] Xaa155 is Met or Phe;

[0183] Xaa156 is Asn or Ser;

[0184] Xaa157 is Thr or Lys;

[0185] Xaa158 is Ile or Val or Ala;

[0186] Xaa161 is Asn or Ile or His or Ser;

[0187] Xaa162 is Leu or Lys;

[0188] Xaa164 is Ala or Thr;

[0189] Xaa165 is Arg or Gln or Lys;

[0190] Xaa166 is Asp or Glu;

[0191] Xaa168 is Ile or Leu;

[0192] Xaa169 is Asn or Asp;

[0193] Xaa171 is Leu or Ile;

[0194] Xaa172 is Ile or Leu;

[0195] Xaa173 is Gln or Asn or His;

[0196] Xaa175 is Lys or Pro;

[0197] Xaa176 is Ile or Val;

[0198] Xaa177 is Thr or Lys; and

[0199] Xaa178 is Asp or Glu.

[0200] Luteinizing Hormone-Releasing Hormone:

[0201] Xaa1-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-OH

[0202] wherein,

[0203] Xaa1 is pGlu, 5-oxoPro or Gln.

[0204] Melanocyte Stimulating Hormone (MSH):

[0205] Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2

[0206] Atrial Natriuretic Peptide:

[0207] H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Xaa135-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Xaa142-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH

[0208] wherein,

[0209] Xaa135 is Met or Ile; and

[0210] Xaa142 is Gly or Ser.

[0211] Neuromedin B:

[0212] H-Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2

[0213] Human Neuropeptide Y:

[0214] H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-asp-Met-Ala- Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2

[0215] Human Orexin A:

[0216] pGlu-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu- Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2

[0217] Human Peptide YY:

[0218] H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn- Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2

[0219] Human Secretin:

[0220] H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2

[0221] Vasoactive Intestinal Peptide (VIP):

[0222] H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2

[0223] Antibiotic Peptides such as:

2Magainin 1:Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Gly-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Lys-SerMagainin 2:Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Asn-SerCecropin A:Lys-Trp-Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys-Val-Gly-Gln-Ala-Thr-Gln-Ile-Ala-LysCecropin B:Lys-Trp-Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys-Met-Gly-Arg-Asn-Ile-Arg-Asn-Gly-Ile-Val-Lys-Ala-Gly-Pro-Ala-Ile-Ala-Val-Leu-Gly-Glu-Ala-Lys-Ala-Leu.Substance P (SP):Arg-Pro-Leu-Pro-Gln-Glu-Phe-Phe-Gly-Leu-Met-amideBeta Casomorphin-5:Tyr-Pro-Phe-Pro-GlyEndomorphin-2:Tyr-Pro-Phe-Phe-NH2Procolipase:100 aa peptide (X1-Pro-X2-Pro-Arg . . . )EnterostatinVal-Pro-Asp-Pro-ArgGastrin Inhibitory Peptide:Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala- Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe- Val-Asn-Trp-Leu- Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln

[0224] Chromogranin A

[0225] Vasostatin I

[0226] Vasostatin II:

3Leu Pro Val Asn Ser Pro Met Asn Lys Gly Asp ThrGlu Val Met Lys Cys Ile Val Glu Val Ile Ser AspThr Leu Ser Lys Pro Ser Pro Met Pro Val Ser GlnGlu Cys Phe Glu Thr Leu Arg Gly Asp Glu Arg IleLeu Ser Ile Leu Arg His Gln Asn Leu Leu Lys GluLeu Gln Asp Leu Ala Leu Gln Gly Ala Lys Glu ArgAla His Gln Gln Lys Lys His Ser Gly Phe Glu AspGlu Leu Ser Glu Val Leu Glu Asn Gln Ser Ser GlnAla Glu Leu Lys Glu Ala Val Glu Glu Pro Ser SerLys Asp Val Met Glu

[0227] Procalcitonin

[0228] ProNCT

[0229] ProCGRP

[0230] Chemokine Family:

[0231] CXC-Group:

[0232] IL8(Monocyte-Derived):

[0233] SerAlaLysGluLeuArgCysGlnCys . . .

[0234] GCP-2:

[0235] GlyProValSerAlaValLeuThrGluLeuArgCysThrCys . . .

[0236] PF4:

[0237] GluAlaGluGluAspGlyAspLeuGlnCysLeuCys . . .

[0238] IP-10:

[0239] ValProLeuSerArgThrValArgCCysThrCys . . .

[0240] MIG:

[0241] ThrProValValArgLysGlyArgCysSerCys . . .

[0242] SDF-1α:

[0243] LysProValSerLeuSerTyrArgCysProCys . . .

[0244] GROα:

[0245] AlaProLeuAlaThrGluLeuArgCysGlnCys . . .

[0246] I-TAC:

[0247] PheProMetPheLysLysGlyArgCysLeuCys . . .

[0248] CC-Group:

[0249] RANTES:

[0250] SerProTyrSerSerAspThrThrProCys . . .

[0251] LD78:

[0252] AlaProLeuAlaAlaAspThrProThrAlaCys . . .

[0253] MIP-1α:

[0254] AlaProMetGlySerAspProProThrAlaCys . . .

[0255] MCP-1:

[0256] GlnProAspAlaIleAsnAlaProValThrCys . . .

[0257] MCP-2:

[0258] GlnProSerAspValSerIleProIleThrCys . . .

[0259] MCP-3:

[0260] GlnProValGlyIleTAsnSeerThrThrCys . . .

[0261] MCP-4:

[0262] GlnProAspAlaLeuAspValProSerThrCys . . .

[0263] Eotaxin:

[0264] GlyProAlaSerValProThrThrCys . . .

[0265] MDC:

[0266] GlyProTyrGlyAlaAsnMetGluAspSerValCys . . .

[0267] and functional derivatives or fragments thereof.

[0268] The complete definition of the previously listed sequences are known inter alia from Mentlein, R (1999) Regul. Pept. 85:9-24 and from De Meester, I. Et al. (2000) Adv ExpMed Biol. 477:67-87. Those documents are incorporated by reference to the present application.

[0269] In a more preferred embodiment, the peptide is substituted with one or more conformationally rigid moieties. Preferred structures of the conformationally rigid moieties comprise those with a double bond, a triple bond or a saturated or unsaturated ring.

[0270] The following is a brief list of the formula of preferred conformationally rigid moieties, identified as Formula 1 to 63, which are suitable for the purposes of the present invention.

[0271] Among the preferred modified peptides according to the present invention, are those wherein the peptide sequence is the sequence of a natural peptide.

[0272] wherein, R is hydrogen, CH3 or CH2CH3.

[0273] A preferred embodiment of the present invention is constituted by peptides wherein the peptide sequence is Somatostatin and at least one conformationally rigid moiety is coupled with said somatostatin peptide sequence via an amide bond at different positions as follows:

4Positionconformationally rigid moietiesAla1

Asp5

Cys14

Ala1 + Cys14

[0274] An another preferred embodiment of the present invention is constituted by those peptides wherein the peptide sequence is PTH 1-34 and at least one conformationally rigid moiety is coupled with said PTH 1-34 peptide sequence via an amide bond at different positions as follows:

5Positionconformationally rigid moietiesSer1

Glu4

Lys26

Lys27

Asp30

Ser1 +Lys27

[0275] A further preferred embodiment of the present invention is constituted by those peptides wherein the peptide sequence is GLP-1 and at least one conformationally rigid moiety is coupled with said GLP-1 peptide sequence via an amide bond at different positions as follows:

6Positionconformationally rigid moietiesHis1

Glu3

Asp9

His1 + Glu3

His1 + Asp9

Glu3 + Asp9

[0276] Also preferred among the modified peptides according to the invention are those peptides wherein;

[0277] the peptide sequence is GLP-2 and at least one conformationally rigid moiety is coupled with said GLP-2 peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0278] the peptide sequence is Enterostatin and at least one conformationally rigid moiety is coupled with said Enterostatin peptide sequence via an amide bond at different positions of the peptide sequence;

[0279] the peptide sequence is NPY and at least one conformationally rigid moiety is coupled with said NPY peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0280] the peptide sequence is NPYY and at least one conformationally rigid moiety is coupled with said NPYY peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0281] the peptide sequence is Secretin and at least one conformationally rigid moiety is coupled with said Secretin peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0282] the peptide sequence is Vasoactive Intestinal Peptide and at least one conformationally rigid moiety is coupled with said Vasoactive Intestinal Peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0283] the peptide sequence is Gastrin Inhibitory Peptide and at least one conformationally rigid moieties is coupled with said Gastrin inhibitory Peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0284] the peptide sequence is Vasostatin II and at least one conformationally rigid moiety is coupled with said Vasostatin II peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0285] the peptide sequence is RANTES and at least one conformationally rigid moiety is coupled with said RANTES peptide sequence via an amide or ester bond at different positions of the peptide sequence;

[0286] the peptide sequence is Eotaxin and at least one conformationally rigid moiety is coupled with said Eotaxin peptide sequence via an amide or ester bond at different positions of the peptide sequence.

[0287] In the modified peptides of the invention, the conformationally rigid moiety is preferably coupled with said peptide sequence via an amide bond at the N-terminal.

[0288] The modified peptides according to the invention, wherein the conformationally rigid moiety is the formula referenced 60 in the description, are of a particular interest.

[0289] The modified peptides of the present invention can be administered in various ways, such as for example, intravenously, subcutaneously, intradermally, transdermally, intraperitoneally, orally, or topically. The modified peptides of the present invention can also be administered by inhalation, when in a powder form or aerosol form. Furthermore, pharmaceutically acceptable carriers for delivery of modified peptides of the present invention include, without limitation, liposome, nanosome, patch, implant or any delivery devices.

[0290] In addition to the carboxy and amino groups present at the C- and N-terminals respectively of the peptide, other carboxy and amino sites can be available on the peptide chain. For example, if the peptide chain comprises amino acids provided with a carboxylic acid side chain such as aspartic acid and glutamic acid, additional carboxy sites will therefore be available on the chain for amidation. Should the peptide chain comprise amino acids with a carboxamide side chain such as asparagine and glutamine, these also provide additional carboxy groups for amidation by a conformationally rigid moiety, provided that they are accessed synthetically via the corresponding aspartic and glutamic acids. Further, if the peptide comprises amino acids provided with a basic side chain such as arginine, histidine or lysine, additional amino sites will then be available on the chain for amidation by a conformationally rigid moiety. The peptide chain may also include both acidic and basic amino acids, meaning that the conformationally rigid substituents could be coupled to the peptide chain via the N-terminal, the C-terminal, a carboxy site on the peptide chain, an amino site on the peptide chain, or a plurality of these sites.

[0291] The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLE 1

[0292] Synthesis of GLP-1 Analogs

[0293] In accordance with the present invention, at least one of the following conformationally rigid moiety is coupled with the GLP-1 peptide sequence via an amide bond at different positions as follows.

7Positionconformationally rigid moietiesHis1

[0294] hGLP-1 (7-37) Analogs Synthesis

[0295] hGLP-1 (7-37) derivatives modified at the amino terminus with rigid hydrophobic moieties were synthesized using Fmoc chemistry (1), on the Symphony apparatus (Rainin Instrument Co., Inc.). Fmoc-Gly-Wang resin (0.70 mmole/g) and five equivalents of reagents (100 μm scale, amino acids concentration of 200 mM), were used with a time coupling of 30 minutes. The reactions have been monitored by the Kaiser test. The three conformationally rigid moieties introduced at the N-terminus of the hGLP-1 (7-37) are:

[0296] Peptide # 1=(O-Tolylacetic acid-His7)-hGLP-1 (7-37) [O-Tolylacetic acid (13) (10 equivalents per coupling; coupling time 45 min)]

[0297] Peptide # 2=((+,−)-cis-2-Ethylcyclopropylacetic acid -His7)-hGLP-1 (7-37) [(+,−)-cis-2-Ethylcyclopropylacetic acid (60) (7.5 equivalents per coupling: coupling time 60 min)].

[0298] The peptides were cleaved using a TFA cocktail (92% TFA, 2% ethanedithiol, 2% thioanisole, 2% triisopropylsilane, 2% water, 2% (w/v) phenol) for 2 hours. All the analogs have been purified by reverse-phase HPLC. They have been analyzed by analytical HPLC and by MS (MALDI-TOF).

[0299] The synthesis of GLP-1 analogs is well known to the person skilled in the art and is fuirther illustrated by the general references Fmoc Solid Phase Peptide Synthesis. A Practical Approach (2000). Chan, W. C. and White, P. D., Oxford University Press, New York, USA, 346p which are incorporated by reference.

[0300] Biological Assess of GLP-1 Analogs

[0301] Materials & Methods

[0302] Oral Glucose Tolerance Test (OGTT)

[0303] Six-week old female CD1 mice (Charles River) were fasted for at least 16 hours. Mice were given 1.5 mg of glucose per gram of body weight orally in water through a gastric savage tube at t=o min and blood was collected from a tail vein at t=0, 10, 20, 30, 60, 90 and 120 min for measurement of blood glucose using a glucose meter (Lifescan). Peptides or vehicle were injected subcutaneously 5 min prior to the glucose administration. Data were expressed as the area under the curve, calculated from the change (delta) in blood glucose for each time, using the trapezoidal rule. Therefore, the data represent the integrated increase in blood glucose over a 120 min period following glucose administration. Data presented are the mean±SEM of 4 to 11 animals per group.

[0304] Test Articles

[0305] All peptides, including wild-type GLP-1 (7-37), were tested in the OGTT test at 3 different concentrations: 1, 5 and 10 ug per mouse. In a first set of experiments (study A), peptide 3 was tested in comparison with vehicle and hGLP-1(7-37). In a second set of experiments (study B), peptides 1 and 2 were tested in comparison with vehicle and hGLP-1 (7-37).

[0306] wt GLP1: hGLP(7-37)

[0307] Peptide #1: (O-Tolylacetic acid-His7)-hGLP-1 (7-37)

[0308] Peptide #2: ((+,−)-cis-2-Ethylcyclopropylacetic acid-His7)-hGLP-1 (7-37)

[0309] Peptide #3: (Hexanoyl-trans-3-His7)-hGLP-1 (7-37)

[0310] Results and Conclusions

[0311] Results are shown in FIG. I (study A) and FIG. II (study B)

[0312] In studies A and B, administration of vehicle resulted in a similar integrated response in glucose levels (study A: 380±57 vs study B: 309±68 mM×120 min), illustrating the validity and reproducibility of the methodology. Although wt GLP-1 induced a dose-related decrease in the glucose response, this peptide was not able to completely suppress the glucose response at any dose, which might be interpreted as a limitation in its potential clinical usefulness. In contrast, peptide 3 (study A, FIG. 1) was able to completely abolish the glucose response, but only at the 10 ug dose (9±26 mM×120 min). Surprisingly, peptide 2 (study B, FIG. 2) was even more potent than peptide 3, being able to totally prevent the glucose response both at the 5 ug and the 10 ug doses (5 ug: −17±67 mM×120 min; 10 ug: 61±64 mM×120 min). In conclusion, the GLP-1 analog corresponding to peptide 2 was identified with marked increased biological potency over the wild type GLP-1 (7-37), because of this increased potency, this peptide may have clinical usefulness in treating states of insulin resistance associated with pathologies such as type II diabetes.

8Positionconformationally rigid moietiesGlu3

Asp9

His1 + Glu3

His1 + Asp9

Glu3 + Asp9

EXAMPLE 2

[0313] PTH 1-34 Analogs

[0314] In accordance with the present invention, at least one of the following conformationally rigid moiety is coupled with the PTH 1-34 peptide sequence via an amide bond at different positions as follows.

9Positionconformationally rigid moietiesSer1

Glu4

Lys26

Lys27

Asp30

Ser1 +Lys27

EXAMPLE 3

[0315] Somatostatin Analogs

[0316] In accordance with the present invention, at least one of the following conformationally rigid moiety is coupled with the somatostatin peptide sequence via an amide bonds at different position as follows.

10Positionconformationally rigid moietiesAla1

Asp5

Cys14

Ala1 + Cys14

[0317] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention, and including such departures from the present description as come within known or customary practice within the art to which the invention pertains, and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

Claims

1. A peptide of formula Xn—R1 wherein: R1 is a peptide sequence, a functional analog thereof or a fragment thereof; each X can be identical or independent from the others and is selected from the following list constituted by conformationally rigid moieties: i) a straight, substituted C1-C10 alkyl; ii) a branched, substituted C1-C10 alkyl; iii) a straight or branched, unsubstituted or substituted C1-C10 alkene; iv) a straight or branched, unsubstituted or substituted C1-C10 alkyne; v) an unsubstituted or substituted, saturated or unsaturated C3-C10 cycloalkyl or heterocycloalkyl wherein the heteroatom is O, S or N; vi) an unsubstituted or substituted C5-C14 aryl or heteroaryl wherein the heteroatom is O, S or N; wherein the substituent in the definitions i) to vi) comprises one or more a) straight or branched C1-C6 alkyl; b) straight or branched C1-C6 alkene; c) straight or branched C1-C6 alkyne; d) C3-C10 cycloalkyl or heterocycloalkyl wherein at least 2 carbon atoms are optionally connected to the C1-C10 alkyl, C1-C10 alkene, C1-C10 alkyne, C3-C10 cycloalkyl or heterocycloalkyl, and C5-C14 aryl or heteroaryl; or e) C5-C14 aryl or heteroaryl wherein at least 2 carbon atoms of the aryl or heteroaryl are optionally connected to the C1-C10 alkyl, C1-C10 alkene, C1-C10 alkyne, C3-C10 cycloalkyl or heterocycloalkyl, and C5-C14 aryl or heteroaryl, said group X also comprising at least one group selected from: α) a carboxy or an amino group for coupling with the peptide sequence via an amide bond at the N-terminal of the peptide sequence, the C-terminal of the peptide sequence, at an available carboxy or amino site on the peptide sequence chain, and combinations thereof; and β) a carboxy group for coupling with the peptide sequence via an ester bond at an available hydroxy site on the peptide sequence chain, and combinations thereof; wherein, n is any digit between 1 to 5; and any isomers thereof, including cis and trans configurations, epimers, enantiomers, diastereoisomers, and racemic mixtures, the peptides defined in claim 1 of U.S. Pat. No. 6,020,311 being excluded.
2. A peptide as claimed in claim 1 wherein the peptide sequence is selected from the group consisting of Growth hormone releasing factor (GRF), Somatostatin, Glucagon-like peptide 1 (7-37), amide human (GLP-1) hGLP-1 (7-36) NH2, Parathyroid hormone fragments (PTH 1-34), Adrenocorticotropic hormone (ACTH), Osteocalcin, Calcitonin, Corticotropin releasing factor, Dynorphin A, β-Endorphin, Big Gastrin-1, GLP-2, Luteinizing hormone-releasing hormone, Melanocyte Stimulating Hormone (MSH), Atrial Natriuretic Peptide, Neuromedin B, Human Neuropeptide Y, Human Orexin A, Human Peptide YY, Human Secretin, Vasoactive Intestinal peptide (VIP), Antibiotic peptides (Magainin 1, Magainin 2, Cecropin A, and Cecropin B), Substance P (SP), Beta Casomorphin-5, Endomorphin-2, Procolipase, Enterostatin, gastric inhibitory peptide, Chromogranin A, Vasostatin I & II, Procalcitonin, ProNCT, CGRP (Calcitonin Gene Related Peptide), IL8 (monocyte-derived), GCP-2, PF4, IP-10, MIG, SDF-1α, GRO-α, I-TAC, RANTES, LD78, MIP-1α, MCP-1, MCP-2, MCP-3, MCP-4, Eotaxin, MDC, and functional analogs and derivatives or fragments thereof.
3. A peptide as claimed in claim 1 or 2 wherein the conformationally rigid moiety comprises at least a double bond, a triple bond or a saturated or unsaturated ring.
4. A peptide as claimed in any one of claims 1 to 3 wherein the conformationally rigid moiety comprises one or more of the structures of Formula 1 to 63 as defined in the description.
5. A peptide as claimed in any one of claims 1 to 4 wherein the peptide sequence is selected from the group consisting of:
6. A peptide according to claim 5 wherein the peptide sequence is the sequence of a natural peptide and functional analog or a fragment thereof or a clinically safe and acceptable derivative or analog thereof.
7. A peptide as claimed in claim 1 wherein the peptide sequence is Somatostatin and at least one conformationally rigid moiety is coupled with said somatostatin peptide sequence via an amide bond at different positions as follows:
8. A peptide as claimed in claim 1 wherein the peptide sequence is PTH 1-34 and at least one conformationally rigid moiety is coupled with said PTH 1-34 peptide sequence via an amide bond at different positions as follows:
9. A peptide as claimed in claim 1 wherein said peptide sequence is GLP-1 and at least one conformationally rigid moiety is coupled with said GLP-1 peptide sequence via an amide bond at different positions as follows:
10. A peptide as claimed in claim 1 wherein said peptide sequence is GLP-2 and at least one conformationally rigid moiety is coupled with said GLP-2 peptide sequence via an amide or ester bond at different positions of the peptide sequence.
11. A peptide as claimed in claim 1 wherein said peptide sequence is Enterostatin and at least one conformationally rigid moiety is coupled with said Enterostatin peptide sequence via an amide bond at different positions of the peptide sequence.
12. A peptide as claimed in claim 1 wherein said peptide sequence is NPY and at least one conformationally rigid moiety is coupled with said NPY peptide sequence via an amide or ester bond at different positions of the peptide sequence.
13. A peptide as claimed in claim 1 wherein said peptide sequence is NPYY and at least one conformationally rigid moiety is coupled with said NPYY peptide sequence via an amide or ester bond at different positions of the peptide sequence.
14. A peptide as claimed in claim 1 wherein said peptide sequence is Secretin and at least one conformationally rigid moiety is coupled with said Secretin peptide sequence via an amide or ester bond at different positions of the peptide sequence.
15. A peptide as claimed in claim 1 wherein said peptide sequence is Vasoactive Intestinal Peptide and at least one conformationally rigid moiety is coupled with said Vasoactive Intestinal Peptide sequence via an amide or ester bond at different positions of the peptide sequence.
16. A peptide as claimed in claim 1 wherein said peptide sequence is Gastrin Inhibitory Peptide and at least one conformationally rigid moiety is coupled with said Gastrin Inhibitory Peptide sequence via an amide or ester bond at different positions of the peptide sequence.
17. A peptide as claimed in claim 1 wherein said peptide sequence is Vasostatin II and at least one conformationally rigid moiety is coupled with said Vasostatin II peptide sequence via an amide or ester bond at different positions of the peptide sequence.
18. A peptide as claimed in claim 1 wherein said peptide sequence is RANTES and at least one conformationally rigid moiety is coupled with said RANTES peptide sequence via an amide or ester bond at different positions of the peptide sequence.
19. A peptide as claimed in claim 1 wherein said peptide sequence is Eotaxin and at least one conformationally rigid moiety is coupled with said Eotaxin peptide sequence via an amide or ester bond at different positions of the peptide sequence.
20. A peptide as in any one of claims 1 to 18, wherein said conformationally rigid moiety is coupled with said peptide sequence via an amide or ester bond at the N-terminal.
21. A peptide according to any one of claims 8 to 19, wherein the conformationally rigid moiety has the formula 60 referenced in the description.
22. A peptide according to claim 20, wherein the peptide sequence is GLP-1.
23. Use of the peptide according to claim 22 in the treatment of glucose intolerance associated or not with insulin resistance pathologies.
24. Use according to claim 23 in the treatment of type II diabetes.
25. A peptide according to claim 1 wherein said peptide sequence is CGRP and at least one conformationally rigid moiety is coupled with said CGRP peptide sequence via an amide or ester bond at different positions of the peptide sequence.

PCT Information

Filing Document	Filing Date	Country	Kind
PCT/CA01/01119	8/2/2001	WO

Modified biological peptides with increased potency

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

PCT Information